Screener
Gyre Therapeutics, Inc. GYRE GNI — Milestone Payments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept gyre:MilestonePayments.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
FAQ
- What is Gyre Therapeutics, Inc.'s GNI — milestone payments?
- Gyre Therapeutics, Inc. (GYRE) reported GNI — milestone payments of $33.1M in Q2 2026.
- What does GNI — milestone payments mean?
- This metric captures the revenue or cash inflows triggered by the achievement of specific clinical, regulatory, or commercial milestones in a drug development program. These payments are critical indicators of progress in the product lifecycle and the successful execution of licensing agreements. It provides insight into the company's ability to monetize its intellectual property through collaborative development.
Ask your AI about Gyre Therapeutics, Inc.'s gni — milestone payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude